Predict your next investment

Venture Capital
quakerbio.com

See what CB Insights has to offer

Investments

118

Portfolio Exits

33

Funds

5

Service Providers

1

About Quaker BioVentures

Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.

Quaker BioVentures Headquarters Location

Cira Centre 2929 Arch Street

Philadelphia, Pennsylvania, 19104-2868,

United States

215-988-6800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Quaker BioVentures News

$20M in Financing Helps RainDance Summon ThunderStorms for Myriad

Apr 30, 2013

The venture investors in RainDance that participated in the Series E round included Mohr Davidow Ventures, Quaker BioVentures, Alloy Ventures, Acadia Woods Partners, and Sectoral Asset Management. RainDance plans to use the proceeds of this ...See all stories on this topic »

Jun 27, 2011
NovaSom Inks $35M

Quaker BioVentures Investments

118 Investments

Quaker BioVentures has made 118 investments. Their latest investment was in Minti as part of their Seed VC on June 6, 2021.

CBI Logo

Quaker BioVentures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/1/2021

Seed VC

Minti

$1M

Yes

1

5/29/2019

Series D

Intact Vascular

$25M

No

2

5/29/2019

Series B

Vesper Medical

$37M

No

5

2/15/2019

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

5/21/2018

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/1/2021

5/29/2019

5/29/2019

2/15/2019

5/21/2018

Round

Seed VC

Series D

Series B

Seed VC

Series A - II

Company

Minti

Intact Vascular

Vesper Medical

Subscribe to see more

Subscribe to see more

Amount

$1M

$25M

$37M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

5

10

10

Quaker BioVentures Portfolio Exits

33 Portfolio Exits

Quaker BioVentures has 33 portfolio exits. Their latest portfolio exit was Vesper Medical on December 14, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/14/2021

Acquired

$99M

5

7/20/2021

Acquired

$99M

1

7/16/2021

IPO

$99M

Public

4

8/27/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/8/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/14/2021

7/20/2021

7/16/2021

8/27/2020

11/8/2019

Exit

Acquired

Acquired

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

5

1

4

10

10

Quaker BioVentures Fund History

5 Fund Histories

Quaker BioVentures has 5 funds, including Quaker BioVentures II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/28/2008

Quaker BioVentures II LP

Late-Stage Venture Capital

Closed

$420M

1

12/31/2004

Quaker BioVentures

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2004

Garden State Life Sciences Venture Fund

Subscribe to see more

Subscribe to see more

$99M

10

9/23/2004

BioAdvance Ventures LP

Subscribe to see more

Subscribe to see more

$99M

10

8/26/2004

Quaker BioVentures Tobacco Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/28/2008

12/31/2004

12/31/2004

9/23/2004

8/26/2004

Fund

Quaker BioVentures II LP

Quaker BioVentures

Garden State Life Sciences Venture Fund

BioAdvance Ventures LP

Quaker BioVentures Tobacco Fund

Fund Type

Late-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$420M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Quaker BioVentures Service Providers

1 Service Provider

Quaker BioVentures has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Quaker BioVentures Team

5 Team Members

Quaker BioVentures has 5 team members, including current Chief Financial Officer, Eric Emrich.

Name

Work History

Title

Status

Eric Emrich

Chief Financial Officer

Current

George Harris

Controller

Current

Brenda D. Gavin

Managing Partner

Current

Richard S. Kollender

Managing Partner

Current

Christine Caruso

Context Capital Partners

Controller

Former

Name

Eric Emrich

George Harris

Brenda D. Gavin

Richard S. Kollender

Christine Caruso

Work History

Context Capital Partners

Title

Chief Financial Officer

Controller

Managing Partner

Managing Partner

Controller

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.